Physician profile
Omid Nikrouz
NPI 1073775912
$7,173.56
in general payments reported to CMS, 2019-2025
25 companies · $2,038 in 2025
The $2,038 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $246 · 2021: $524 · 2022: $781 · 2023: $1,692 · 2024: $1,530 · 2025: $2,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,259.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,270.23 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,237.21 | 2021-2025 | |
| Glaxosmithkline, LLC. | $759.49 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $640.73 | 2023-2025 | |
| Amgen INC. | $466.75 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $432.69 | 2022-2024 | Freestyle Libre 3 |
| Gilead Sciences, INC. | $386.77 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $303.08 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $288.02 | 2025 | Symbravo |
| Horizon Therapeutics Plc | $249.99 | 2019-2022 | |
| Viiv Healthcare Company | $200.45 | 2022-2025 | Apretude |
| Allergan, INC. | $147.10 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $140.00 | 2025 | |
| Progenics Pharmaceuticals, INC. | $125.00 | 2023 | Pylarify |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.94 | 2023 | Cycloset |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuity Medical INC | $111.11 | 2022 | |
| Bausch Health US, LLC | $94.00 | 2021-2022 | |
| Exact Sciences Corporation | $80.27 | 2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $23.72 | 2023 | Mounjaro |
| Ultragenyx Pharmaceutical INC. | $19.42 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.05 | 2023 | Gvoke Hypopen |
| Vbi Vaccine (Delaware) INC. | $15.63 | 2022 | |
| Phadia US INC. | $14.39 | 2024 | Immunocap |
| Incyte Corporation | $14.26 | 2023 | Opzelura |
| Biohaven Pharmaceuticals, INC. | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omid Nikrouz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.